Purpose Anaplastic lymphoma kinase (ALK) rearrangement–positive non–small-cell lung
cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as …

The clinical management/understanding of brain metastases (BM) has changed
substantially in the last 5 years, with key advances and clinical trials highlighted in this …

作者单位: 100021 北京, 中国医学科学院北京协和医学院肿瘤医院, 抗肿瘤分子靶向药物临床
研究北京市重点实验室(石远凯, 孙燕, 韩晓红, 郏博, 韩颖, 黄昱); 250117 济南 …

Rearrangements of the ROS1 gene occur in 1–2% of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

Abstract On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for
the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors …

Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared
prospectively in the phase III PROFILE 1014 study in ALK-positive non–small-cell lung …

Background There is currently no Europe-wide consensus on the appropriate preanalytical
measures and workflow to optimise procedures for tissue-based molecular testing of non …

This systematic review aims to improve understanding of the burden of disease associated
with brain metastases from non-small-cell lung cancer (NSCLC) in terms of survival, quality …

Intrahepatic cholangiocarcinoma (iCCA) is a molecularly heterogeneous hepatobiliary
neoplasm with poor prognosis and limited therapeutic options. The incidence of this …

Introduction Lung cancer is the leading cause of years of life lost because of cancer and is
associated with the highest economic burden relative to other tumor types. Research …